ADB-4en-PINACA

Synthetic cannabinoid
| ADB-4en-PINACA
| |
|---|---|
| Chemical nomenclature | |
| IUPAC name | N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobutyl)-1H-indazole-3-carboxamide
|
| Chemical data
| |
| Chemical formula | C18H26N3O2F1
|
ADB-4en-PINACA is a synthetic cannabinoid that has been identified in synthetic cannabis products. It is a potent agonist of the CB1 receptor and CB2 receptor, which are part of the endocannabinoid system.
Chemical Structure[edit]
ADB-4en-PINACA belongs to the indazole family of synthetic cannabinoids. Its chemical structure includes a fluorobutyl side chain, which is a distinguishing feature among synthetic cannabinoids. The IUPAC name for ADB-4en-PINACA is N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobutyl)-1H-indazole-3-carboxamide.
Pharmacology[edit]
As a synthetic cannabinoid, ADB-4en-PINACA acts on the CB1 receptor and CB2 receptor in the endocannabinoid system. These receptors are primarily found in the central nervous system and immune system, respectively. The activation of these receptors by synthetic cannabinoids can lead to a range of effects, including euphoria, anxiety, and hallucinations.
Legal Status[edit]
The legal status of ADB-4en-PINACA varies by country. In some jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. For example, in the United States, synthetic cannabinoids are often regulated under the Controlled Substances Act.
Health Risks[edit]
The use of ADB-4en-PINACA has been associated with a number of adverse health effects. These can include tachycardia, hypertension, nausea, and vomiting. In severe cases, it can lead to psychosis and seizures. Due to these risks, the use of synthetic cannabinoids like ADB-4en-PINACA is generally discouraged.
See Also[edit]
References[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian